# ILiAD Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iliad-biotechnologies

- Industry: Biotechnology
- Headquarters: US
- Website: www.iliadbio.com
- Total disclosed funding: $115M
- Latest round: Series B (Feb 10, 2026)
- Investors on record: 4

## About

Based in Florida, US, and founded in 2012, ILiAD Biotechnologies, LLC operates as a clinical-stage biotechnology company that develops vaccines to eradicate infectious diseases. In February 2026, ILiAD Biotechnologies raised USD 115 million in series B funding led by RA Capital Management, with participation from Janus Henderson Investors, BNP Paribas Asset Management, and AI Life Sciences Investments.

ILiAD Biotechnologies, LLC offers a B-Tech vector platform that has developed BPZE1, a live attenuated pertussis vaccine that contains genetic modifications to eliminate, attenuate or inactivate three different B. pertussis toxins. It induces both mucosal and systemic immune responses, with the potential and immunity compared to the current intramuscular injection of purified pertussis antigens such as aPV.

The company plans to use the series D funding to conduct a Phase 2b Human challenge study to determine vaccination with BPZE1 prevents colonization from wild-type Bordetella pertussis infection.

## Funding rounds

- Series B, Feb 10, 2026, $115M — BNP Paribas Asset Management, RA Capital Management, Janus Henderson Investors, AI Life Sciences Investments

## Investors

- BNP Paribas Asset Management (https://capitalatlas.ai/funds/bnp-paribas-asset-management) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Janus Henderson Investors — Series B
- AI Life Sciences Investments — Series B